Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped up before the market opened on Wednesday . The stock had previously closed at $17.07, but opened at $17.75. Ascentage Pharma Group International shares last traded at $17.65, with a volume of 1,045 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AAPG. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday. They issued a “buy” rating and a $45.00 price target for the company. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. Finally, BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Trading Up 0.2%

The company’s 50-day simple moving average is $22.27 and its 200-day simple moving average is $24.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. Sell-side analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $383,000. XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International during the third quarter valued at approximately $204,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.